[Therapeutic effect of alpha-tocopher- yl-quinone on muscular disorders of hyperthyroidism and of prolonged treatment by corticoids and antimitotics].
D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001247:Asthenia / Q000139:chemically induced; D002066:Busulfan / Q000009:adverse effects; D002699:Chlorambucil / Q000009:adverse effects; D003036:Cobalt Isotopes / Q000009:adverse effects; D003286:Contracture / Q000139:chemically induced; D003348:Cortisone / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003882:Dermatomyositis / Q000188:drug therapy; D004614:Emaciation / Q000139:chemically induced; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009133:Muscular Atrophy / Q000139:chemically induced / Q000188:drug therapy*; D009136:Muscular Dystrophies / Q000139:chemically induced / Q000188:drug therapy*; D011241:Prednisone / Q000009:adverse effects; D014747:Vinblastine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects; D014810:Vitamin E / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D003036:Cobalt Isotopes; D014810:Vitamin E; D002699:Chlorambucil; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D002066:Busulfan; D003348:Cortisone; D011241:Prednisone
Activité thérapeutique de l'alpha-tocophéryl-quinone sur les désordres musculaires de l'hyperthyroïdie et des traitements prolongés par les corticoïdes et les antimitotiques.